483
Jiangsu Anbison Pharmaceutical Co., Ltd.Jiangsu Anbison Pharmaceutical Co., Ltd. – FDA 483, Jul 16, 2024
Record Details
An FDA inspection of Jiangsu Anbison Pharmaceutical Co., Ltd. in Taizhou, China, revealed significant deficiencies in their manufacturing operations. Observations included inadequate quality control unit procedures for reviewing audit trails, insufficient validation of aseptic processes for sterile drug products, and deficiencies in environmental monitoring within aseptic processing areas. These issues indicate a lack of control over critical manufacturing processes and data integrity.
View Company Profile
ID · 1f15e594-e0fe-4ce3-89a0-012e7b14b791
Other documents for Jiangsu Anbison Pharmaceutical Co., Ltd.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.